Premium
[O2–01–02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSS‐VALIDATED METHOD THAT PREDICTS CEREBRAL β‐AMYLOIDOSIS
Author(s) -
Palmqvist Sebastian,
Insel Philip,
Stomrud Erik,
Mattsson Niklas,
Hansson Oskar
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.144
Subject(s) - alzheimer's disease neuroimaging initiative , recall , medicine , cohort , area under the curve , amyloidosis , psychology , receiver operating characteristic , fornix , audiology , dementia , disease , hippocampus , cognitive psychology
preclinical AD in between. Evaluating SCD-plus criteria as indicators of preclinical AD, we found that age>60 (Odds Ratio 7.7(95%CI 1.738.9)) and APOE e4 (OR 4.8(1.6-15.0)) were independently associated with preclinical AD, while caregiver report (OR 1.9(0.6-5.7)) and onset<5 years (OR 0.9(0.3-2.7)) were not. Conclusions:The SCIENCe project extensively investigates factors potentially related to the subjective experience of cognitive decline. Evaluation of the first 151 participants revealed a heterogeneous group, with besides preclinical AD also subthreshold psychiatric features, and roughly half having no clear origin of complaints. Furthermore, some, but not all, SCD-plus criteria were associated with preclinical AD.